A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant Depression - COMPASS Pathways (ClinicalTrials.gov, 2026)
Exported from Psilocybin Research Publication Tracker: https://psilocybin-research.com